CN104069194A - A traditional Chinese medicine composition having anticancer effects and a preparing method and uses thereof - Google Patents
A traditional Chinese medicine composition having anticancer effects and a preparing method and uses thereof Download PDFInfo
- Publication number
- CN104069194A CN104069194A CN201310100488.0A CN201310100488A CN104069194A CN 104069194 A CN104069194 A CN 104069194A CN 201310100488 A CN201310100488 A CN 201310100488A CN 104069194 A CN104069194 A CN 104069194A
- Authority
- CN
- China
- Prior art keywords
- paeoniae alba
- angelicae sinensis
- radix
- chinese medicine
- radix paeoniae
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention provides a traditional Chinese medicine composition having anticancer effects and a preparing method and uses thereof. The traditional Chinese medicine composition mainly comprises following raw material medicines: white paeony root and Chinese angelica. The preparing method includes: weighing the raw material medicines according to a ratio, and extracting with water or an organic solvent mutually soluble with water; or weighing the raw material medicines according to the ratio and preparing by adoption of a water extraction and alcohol precipitation method, wherein the alcohol precipitation concentration is 50-90. The uses of the composition relate to applications of the composition in preparation of medicines treating cancer especially medicines treating cervical cancer. The composition comprises the white paeony root and the Chinese angelica in a weight ratio of 1:(0.2-4). By compatibility of the white paeony root and the Chinese angelica, the composition has coordinate repression effects for Hela cells and has good anticancer effects.
Description
Technical field
The present invention relates to a kind of Chinese medicine composition and its production and use, be specifically related to a kind of Chinese medicine composition with antitumaous effect and its production and use, belong to Chinese medicine technical field.
Background technology
Cancer is the major disease that jeopardizes human health, and its fatality rate is the trend rising year by year, and its generation and development are the complex lesions processes of multifactor participation, polygenes change and Multi stage development.At present mostly adopt operative treatment in conjunction with Radiotherapy chemotherapy method for the treatment of cancer, but the method is large to patient's wound, dangerous high, and somewhat expensive, but curative effect is unsatisfactory.The weapon that Chinese medicine is prevented and cured diseases as China's tradition, is accompanied by recent years progressively deep research and discovery, in treatment of cancer, more and more comes into one's own.Research shows, in treatment and prevention of tumour process, Chinese medicine is mainly from improving that body's immunity, inducing apoptosis of tumour cell, inhibition tumor cell shift and the aspect such as attenuation synergistic to chemotherapy plays a role.
Chinese medicine composition compatibility of the present invention is reasonable, can regulate negative and positive of qi and blood and function, and protection hemopoietic function of bone marrow, can start again self-defense system, improves immunity of organisms, very helpful for the auxiliary treatment of tumor.
Summary of the invention
First object of the present invention is to provide a kind of Chinese medicine composition with antitumaous effect.
Second object of the present invention is to provide the preparation method of said composition.
The 3rd object of the present invention is to provide the application of said composition in preparation treatment cancer drug.
The 4th object of the present invention is to provide the application of said composition in preparation treatment cervical cancer medicine.
The object of the invention is to be achieved through the following technical solutions:
Have a Chinese medicine composition for antitumaous effect, this Chinese medicine composition is made up of the crude drug of following weight ratio:
The Radix Paeoniae Alba: Radix Angelicae Sinensis=1:(0.2-4).
The crude drug of described Chinese medicine composition is preferably:
The Radix Paeoniae Alba: Radix Angelicae Sinensis=1:(0.3-3.5).
The crude drug of described Chinese medicine composition is preferably:
The Radix Paeoniae Alba: Radix Angelicae Sinensis=1:(0.4-3).
The crude drug of described Chinese medicine composition is preferably:
The Radix Paeoniae Alba: Radix Angelicae Sinensis=1:(0.5-2.5).
The crude drug of described Chinese medicine composition is preferably:
The Radix Paeoniae Alba: Radix Angelicae Sinensis=1:(0.5-2.2).
The crude drug of described Chinese medicine composition is preferably:
The Radix Paeoniae Alba: Radix Angelicae Sinensis=1:(0.5-2).
The crude drug of described Chinese medicine composition is more preferably:
The Radix Paeoniae Alba: Radix Angelicae Sinensis=1:0.5;
Or, the Radix Paeoniae Alba: Radix Angelicae Sinensis=1:1;
Or, the Radix Paeoniae Alba: Radix Angelicae Sinensis=1:2.
Chinese medicine composition of the present invention routinely technique is prepared into clinical acceptable granule, tablet, capsule, drop pill, oral liquid, suspension, emulsion, injection.
Chinese medicine composition of the present invention can be prepared as follows:
Get in proportion crude drug, the organic solvent extraction dissolving each other with water or with water;
Further, the described organic solvent dissolving each other with water is selected from one or more in methanol, ethanol, acetone; Further be preferably the ethanol of 50-90%; Further be preferably the ethanol of 60-80%; Further be preferably 70% ethanol;
Extracting method used comprises any one mode decocting in extraction, reflux, extract,, immersion extraction, supersound extraction or percolation extraction, or the combination of Different Extraction Method.
Chinese medicine composition of the present invention also can adopt: get in proportion crude drug, adopt decoction and alcohol sedimentation technique preparation; Wherein said alcohol precipitation concentration is 50-90%;
Further, described alcohol precipitation concentration is 60-80%; Further described alcohol precipitation concentration is 70%.
Above-mentioned preparation method Raw medicine also can be purified, refining after extracting, as crossed macroporous resin column; And further preparation process is routinely made the acceptable any conventional dosage form of pharmaceutics, comprises granule, tablet, capsule, drop pill, oral liquid, suspension, emulsion, injection.
For above-mentioned dosage form can be realized, need in the time of these dosage forms of preparation, add the acceptable adjuvant of pharmacy, for example: filler, disintegrating agent, lubricant, suspending agent, binding agent, sweeting agent, correctives, antiseptic, substrate etc.Filler comprises: starch, pregelatinized Starch, lactose, mannitol, chitin, microcrystalline Cellulose, sucrose etc.; Disintegrating agent comprises: starch, pregelatinized Starch, microcrystalline Cellulose, carboxymethyl starch sodium, crospolyvinylpyrrolidone, low-substituted hydroxypropyl cellulose, cross-linking sodium carboxymethyl cellulose etc.; Lubricant comprises: magnesium stearate, sodium lauryl sulphate, Pulvis Talci, silicon dioxide etc.; Suspending agent comprises: polyvinylpyrrolidone, microcrystalline Cellulose, sucrose, agar, hydroxypropyl emthylcellulose etc.; Binding agent comprises: starch slurry, polyvinylpyrrolidone, hydroxypropyl emthylcellulose etc.; Sweeting agent comprises: saccharin sodium, Aspartane, sucrose, cyclamate, enoxolone etc.; Correctives comprises: sweeting agent and various essence; Antiseptic comprises: parabens, benzoic acid, sodium benzoate, sorbic acid and its esters, benzalkonium bromide, acetic acid chloroethene are determined, Folium eucalypti globueli (Eucalyptus globulus Labill.) wet goods; Substrate comprises: PEG6000, PEG4000, insect wax etc.For making above-mentioned dosage form can realize pharmacy of Chinese materia medica, need add acceptable other adjuvant of pharmacy (Fan Biting " pharmacy of Chinese materia medica ", the adjuvant that in Shanghai Science Press December in 1997 the 1st edition, each dosage form is recorded) when these dosage forms in preparation.
Chinese medicine composition of the present invention, except the form feeding intake with the Radix Paeoniae Alba, Radix Angelicae Sinensis crude drug, can also adopt the form feeding intake with the Radix Paeoniae Alba, Radix Angelicae Sinensis extract (effective site), therefore the present invention further discloses a kind of Chinese medicine composition with antitumaous effect:
Have a Chinese medicine composition for antitumaous effect, this Chinese medicine composition is made up of the raw material of following weight ratio:
Radix Paeoniae Alba extract: Radix Angelicae Sinensis extract=1:(0.2-4).
The crude drug of described Chinese medicine composition is preferably:
Radix Paeoniae Alba extract: Radix Angelicae Sinensis extract=1:(0.3-3.5).
The crude drug of described Chinese medicine composition is preferably:
Radix Paeoniae Alba extract: Radix Angelicae Sinensis extract=1:(0.4-3).
The crude drug of described Chinese medicine composition is preferably:
Radix Paeoniae Alba extract: Radix Angelicae Sinensis extract=1:(0.5-2.5).
The crude drug of described Chinese medicine composition is preferably:
Radix Paeoniae Alba extract: Radix Angelicae Sinensis extract=1:(0.5-2.2).
The crude drug of described Chinese medicine composition is preferably:
Radix Paeoniae Alba extract: Radix Angelicae Sinensis extract=1:0.5-2.
The crude drug of described Chinese medicine composition is more preferably:
Radix Paeoniae Alba extract: Radix Angelicae Sinensis extract=1:0.5;
Or, Radix Paeoniae Alba extract: Radix Angelicae Sinensis extract=1:1;
Or, Radix Paeoniae Alba extract: Radix Angelicae Sinensis extract=1:2.
The extractive with organic solvent that Radix Paeoniae Alba extract of the present invention and Radix Angelicae Sinensis extract are respectively the water extract of the Radix Paeoniae Alba, Radix Angelicae Sinensis or dissolve each other with water; Or, be respectively the extract that the Radix Paeoniae Alba, Radix Angelicae Sinensis obtain after water extract-alcohol precipitation is processed.
Further, the described organic solvent dissolving each other with water is selected from one or more in methanol, ethanol, acetone; Further be preferably the ethanol of 50-90%; Further be preferably the ethanol of 60-80%; Further be preferably 70% ethanol;
Extracting method used comprises any one mode decocting in extraction, reflux, extract,, immersion extraction, supersound extraction or percolation extraction, or the combination of Different Extraction Method.
Further, described alcohol precipitation concentration is 50-90%; Further preferably alcohol precipitation concentration is 60-80%; Further described alcohol precipitation concentration is 70%.
Decoction and alcohol sedimentation technique of the present invention means in Chinese medicine water extracting liquid, adds ethanol to make to reach the alcohol amount (being alcohol precipitation concentration) that contains of regulation, and some composition dissolubility in alcoholic solution reduces separates out precipitation, filter, get alcoholic solution, reclaim ethanol and obtain extract, make water extraction liquid be able to refining method.
Experimental result shows, the Radix Paeoniae Alba, Radix Angelicae Sinensis, Rhizoma Chuanxiong and Radix Rehmanniae Preparata independent role are in the time of human cervical carcinoma Hela cell, and only the Radix Paeoniae Alba has inhibitory action to the propagation of Hela cell, and suppression ratio can reach 28.6%, and Radix Angelicae Sinensis, Rhizoma Chuanxiong and Radix Rehmanniae Preparata are all without obvious inhibitory action.And Hela cell is played to coordinate repression (CI<1 when the Radix Paeoniae Alba and Radix Angelicae Sinensis compatibility, 0.1<Fa<0.9), the Radix Paeoniae Alba and Rhizoma Chuanxiong compatibility or the Radix Paeoniae Alba and Radix Rehmanniae Preparata compatibility suppress all to rise antagonism (CI>1) to the propagation of Hela cell.
Effect experimental example
The research that experimental example 1 Radix Paeoniae Alba is right
1 material
Human cervical carcinoma Hela cell is so kind as to give by central laboratory of Tianjin Cancer Institute; RPMI-1640 culture medium, GIBCO company of U.S. product;
The Radix Paeoniae Alba, Radix Angelicae Sinensis, Rhizoma Chuanxiong, the each single medicine of Radix Rehmanniae Preparata and the Radix Paeoniae Alba are all adopted preparation with the following method respectively at Radix Angelicae Sinensis, Rhizoma Chuanxiong, Radix Rehmanniae Preparata by " medicine to " of the compositions of different proportion compatibility: get crude drug, soak 30min, add 8 times of water gagings to decoct three times, each 1.5 hours, filter, merging filtrate, centrifugal, dry, pulverize into powder.Xeraphium need to be made into reagent the filtration sterilization of respective concentration with DMEM high glucose medium by experiment.
2 experimental techniques
2.1 Radix Paeoniae Albas, Radix Angelicae Sinensis, Rhizoma Chuanxiong, the impact of Radix Rehmanniae Preparata on Hela cell proliferation
Hela cell is cultivated in 5%CO2 incubator, and culture medium is the RPMI-l640 containing 10% deactivation calf serum, containing 1% dual anti-(penicillin and streptomycin).Within every 2～3 days, go down to posterity once, the trophophase cell of taking the logarithm is for experiment.5000/m1 Hela cell of the every hole inoculation of 24 orifice plate, inoculates dosing in latter 24 hours and cultivates, and establishes the Radix Paeoniae Alba, Radix Angelicae Sinensis, Rhizoma Chuanxiong, Radix Rehmanniae Preparata and negative control group.Add drug level with the following formula each group of In vitro culture that convert: C (μ g/mL)=5D (mg/Kg/d); C is experiment in vitro desired concn, and D is clinical application concentration, and quantity is pressed the each 9g/ of four Chinese medicine and calculated.96 hours collecting cells after dosing, row trypan blue counting.
2.2 impacts of Radix Paeoniae Alba compatibility different pharmaceutical on Hela cell proliferation
The take the logarithm Hela cell of trophophase, trypsinization piping and druming are cell suspension.Centrifugal collecting cell, the cell concentration of adjusting suspension after counting is 1 × 10
4/ mL, is inoculated in 24 porocyte culture plates, every hole 1mL.Choose Hela cell proliferation is had to the obvious inhibiting Radix Paeoniae Alba according to 2.1 experimental results, itself and other drug are used and act on Hela cell by different proportion variable concentrations compatibility, be equipped with alone group of the Radix Paeoniae Alba, Radix Angelicae Sinensis, Radix Rehmanniae Preparata, Rhizoma Chuanxiong, the Radix Paeoniae Alba and Radix Angelicae Sinensis in 1:1,2:1,1:2 ratio compatibility combination group, the Radix Paeoniae Alba and Radix Rehmanniae Preparata in 1:1,2:1,1:2 ratio compatibility combination group, the Radix Paeoniae Alba and Rhizoma Chuanxiong in 1:1,2:1,1:2 ratio compatibility combination group, and negative control group.Add drug level with dosage group In vitro culture in the following formula conversion Radix Paeoniae Alba and different pharmaceutical compatibility: C (μ g/mL)=5D (mg/Kg/d); C is experiment in vitro desired concn, and D is clinical application concentration.Taking this concentration as intermediate concentration, respectively upwards, downward 2 times increase progressively and successively decrease, 6 Concentraton gradient are set continuously.In incubator, cultivate 96h, light is respectively organized cellular morphology through Microscopic observation and is changed, rear collecting cell, row trypan blue counting.
In utilization, imitate principle judgement associating drug effect: middle effect concentration (Dm), be the calculating of half-inhibition concentration (IC50), calculate medicine group cell fu(survival rate fraction of unaffeeted cells according to trypan blue exclusion viable count) and fa(suppression ratio fraetion of affected cells)
The average viable count of the average viable count/matched group of fu=test group
fa=1-fu
Being taken the logarithm in middle efficacious prescriptions journey fa/fu=(D/Dm) m both sides, (D is drug level; Dm is middle effect concentration) equation:
log(fa/fu)=mLogD-mLogDm
Thereby Dx=Dm × [fa/ (l-fa)] l/m
If Y=log (fa/fu), X=logD, obtains linear equation:
The slope of Y=mX+a(m equation, a is equation intercept)
When Fa=0.5, X=logDm=-a/m, the Dm value while calculating the alone and use in conjunction of medicine
Applying this formula Dx=Dm × [fa/ (1-fa)] 1//m calculates and reaches various effects (fa=0.1,0.2,0.3 ... 0.9) the alone and needed drug level of use in conjunction (D) of two kinds of medicines time
CI (The Combination index) value when calculating two medicines and share according to the amount-effect formula in week-Te Shi association index method
Clx=D1/Dxl+D2/Dx2
Attention: Dl in formula, D2 when share, the shared concentration of two medicines when effect reaches X, Dxl, Dx2 was two prescription used times, concentration separately when effect reaches X.In factor alpha basis, effect mapping is determined, when two medicines mappings are parallel to each other, α value is 0, otherwise is 1.
Result is judged: CI<l represents that when two medicines share, producing collaborative (synergism) acts on; CI=1 represents that when two medicines share, producing addition (additivity) acts on; CI>l represents that two medicines produce antagonism (antagonism) effect while share.
Middle effect concentration and associating drug effect are by CalcuSyn computed in software matching chart.
2.3 compatibility of drugs synergism Mechanism Study
The take the logarithm Hela cell of trophophase, after 0.25% trypsinization, collecting cell.Trypan Blue is made viable count (viable count must more than 90%) and is prepared cell suspension, and adjusting cell concentration is every hole 1 × 10
5be inoculated in 6 well culture plates, continue to cultivate 24h, after cell attachment, change liquid dosing, if the Radix Paeoniae Alba alone (250 μ g/mL) group, Radix Angelicae Sinensis alone (125 μ g/mL) group, Radix Paeoniae Alba compatibility Radix Angelicae Sinensis (250 μ g/mL+125 μ g/mL) group and blank group, each experimental group correspondence adds the Contained Serum of the each concentration that accounts for training matrix long-pending 10%, blank group adds equal-volume culture fluid, continue to cultivate collecting cell after 96h, by Drug by Flow Cytometry on Hela cell cycle and apoptotic impact.
The take the logarithm Hela cell of trophophase, adjusting cell concentration is 5 × 10
4/ hole is inoculated in 12 well culture plates, continue to cultivate 24h, after cell attachment, change liquid dosing, if the Radix Paeoniae Alba alone (250 μ g/mL) group, Radix Angelicae Sinensis alone (125 μ g/mL) group, Radix Paeoniae Alba compatibility Radix Angelicae Sinensis (250 μ g/mL+125 μ g/mL) group and the each experimental group correspondence of blank group add the Contained Serum of the each concentration that accounts for training matrix long-pending 10%, blank group adds equal-volume culture fluid, collecting cell after continuation cultivation 96h, Elisa detects the Radix Paeoniae Alba and the impact of Radix Angelicae Sinensis compatibility on Hela cell CyclinD1 expression.
3 statistical method
Application SPSS16.0 statistics analysis software package, experimental data is with mean ± standard deviation
represent, under the condition of testing data normal distribution and homogeneity of variance, between many groups, data relatively adopt variance analysis, respectively organize relatively checking with LSD-t of group difference.With P < 0.05 for there being statistical significance.
4 experimental results
4.1 Radix Paeoniae Albas, Radix Angelicae Sinensis, Rhizoma Chuanxiong, the impact of Radix Rehmanniae Preparata on Hela cell proliferation
Trypan blue counting method detects different experiments group.The Radix Paeoniae Alba has inhibitory action to the propagation of Hela cell, and suppression ratio can reach 28.6%, and the Radix Angelicae Sinensis of same dose, Rhizoma Chuanxiong and Radix Rehmanniae Preparata to Hela cell all without obvious inhibitory action (referring to table 1).
The each experimental group of table 1 is to Hela cell inhibitory rate
| ? | Blank group | The Radix Paeoniae Alba | Rhizoma Chuanxiong | Radix Angelicae Sinensis | Radix Rehmanniae Preparata |
| Crude drug g/d | 0 | 9 | 9 | 9 | 9 |
| Extract g/d | 0 | 2.15 | 2.71 | 3.77 | 4.21 |
| Drug level (μ g/mL) | 0 | 178.92 | 225.83 | 313.85 | 350.50 |
| Suppression ratio | 0 | *28.60 | -0.07 | 0.78 | -2.55 |
* represent and relatively P<0.01 of blank group
4.2 impacts of Radix Paeoniae Alba compatibility different pharmaceutical on Hela cell proliferation
4.2.1 the Radix Paeoniae Alba and the impact of Radix Angelicae Sinensis compatibility on Hela cell proliferation
Trypan blue counting method detects different experiments group: the Radix Paeoniae Alba and Radix Angelicae Sinensis are alone and share (Radix Paeoniae Alba: Radix Angelicae Sinensis=1:1,1:2 and 2:1) viable count after human cervical carcinoma Hela cell's strain 96h, calculate the Fa under the each concentration of each experimental group.The IC50 of application Excel and the CalcuSyn computed in software Radix Paeoniae Alba, Radix Angelicae Sinensis is respectively 109.28 μ g/mL, 721.74 μ g/mL.Calculate the Radix Paeoniae Alba and Radix Angelicae Sinensis and share the CI value to Hela cell in the time of different effect, statistical analysis shows, the Radix Paeoniae Alba and Radix Angelicae Sinensis are pressed 1:1,2:1, all plays coordinate repression to Hela cell when 1:2 ratio compatibility: CI<1 (0.1<Fa<0.9) (referring to table 2-table 4).
The table 2 variable concentrations Radix Paeoniae Alba and Radix Angelicae Sinensis are alone to the cytostatic effect Fa of Hela
Table 3 Radix Paeoniae Alba and Radix Angelicae Sinensis share the cytostatic effect Fa to Hela
Table 4 Radix Paeoniae Alba and the CI index of Radix Angelicae Sinensis different proportion compatibility to Hela Growth of Cells
4.2.2 the Radix Paeoniae Alba and the impact of Radix Rehmanniae Preparata compatibility on Hela cell proliferation
Trypan blue counting method detects different experiments group: the Radix Paeoniae Alba and Radix Rehmanniae Preparata are alone and share (Radix Paeoniae Alba: Radix Rehmanniae Preparata=1:1,1:2 and 2:1) viable count after human cervical carcinoma Hela cell's strain 96h, calculate the cell inhibitory rate under the each concentration of each experimental group.Application Excel and the CalcuSyn computed in software Radix Paeoniae Alba and Radix Rehmanniae Preparata share the association index value (CI) to Hela cell in the time of different effect, statistical analysis shows, the Radix Paeoniae Alba and Radix Rehmanniae Preparata are pressed different proportion compatibility, in the time of 0.1<Fa<0.9, the propagation of Hela cell have been suppressed to antagonism (CI>1), wherein only in the time of the Radix Paeoniae Alba 125 μ g/mL+ Radix Rehmanniae Preparata 62.5 μ g/mL, play slight synergism CI=0.983 (0.1<Fa<0.9) (referring to table 5-7).
The table 5 variable concentrations Radix Paeoniae Alba and Radix Rehmanniae Preparata are alone to the cytostatic effect Fa of Hela
Table 6 Radix Paeoniae Alba and Radix Rehmanniae Preparata share the cytostatic effect Fa to Hela
Table 7 Radix Paeoniae Alba and the CI index of Radix Rehmanniae Preparata different proportion compatibility to Hela Growth of Cells
4.2.3 the Radix Paeoniae Alba and the impact of Rhizoma Chuanxiong compatibility on Hela cell proliferation
Trypan blue exclusion method detects different experiments group and acts on the viable count after Hela cell 96h, calculates cell inhibitory rate.The each combination group CI of application CalcuSyn computed in software shows: the Radix Paeoniae Alba and Rhizoma Chuanxiong are pressed 1:1, when 2:1 ratio compatibility, Hela cell are played to antagonism inhibitory action (CI>1).When the Radix Paeoniae Alba and Rhizoma Chuanxiong 1:2 compatibility, only slight synergism in the time of the Radix Paeoniae Alba 125 μ g/mL+ Rhizoma Chuanxiong 250 μ g/mL, CI=0.96 (0.1<Fa<0.9), more than be antagonistic effect (CI>1) (refer to table 8-10).
The table 8 variable concentrations Radix Paeoniae Alba and Rhizoma Chuanxiong are alone to the cytostatic effect Fa of Hela
Table 9 Radix Paeoniae Alba and Rhizoma Chuanxiong share the cytostatic effect Fa to Hela
Table 10 Radix Paeoniae Alba and the CI index of Rhizoma Chuanxiong different proportion compatibility to Hela Growth of Cells
4.3 compatibility of drugs synergism Mechanism Study
(1) cell cycle result shows: the G0/G1 phase cell of blank group, alone group of the Radix Paeoniae Alba, alone group of Radix Angelicae Sinensis and the Radix Paeoniae Alba 250 μ g/mL compatibility Radix Angelicae Sinensis 125 μ g/mL groups is followed successively by 57.07%, 53.27%, 54.125%, 47.25%, S phase cell is followed successively by 25.4%, 29.53%, 28.94%, 37.61%, G2/M phase cell is followed successively by 17.56%, 17.205%, 16.93%, 14.97%, G0/G1 and S phase cell number, Radix Paeoniae Alba compatibility Radix Angelicae Sinensis group more all has statistical significance (P<0.01) (referring to table 11) with blank group.
Table 11 different experiments group Hela cell cycle testing result
| Group | G0/G1（%） | S（%） | G2/M（%） |
| Blank group | 57.04±0.81 | 25.4±1.38 | 17.56±0.85 |
| The Radix Paeoniae Alba 250 μ g/mL | 53.27±1.84 | 29.53±2.73 | 17.20±0.89 |
| Radix Angelicae Sinensis 125 μ g/mL | 54.12±0.38 | 28.94±0.44 | 16.93±0.14 |
| The Radix Paeoniae Alba 250 μ g/mL+ Radix Angelicae Sinensis 125 μ g/mL | 47.25±1.80* | 37.61±2.32* | 14.97±2.24 |
* represent and relatively P<0.01 of blank experimental group
(2) apoptosis result shows: after the treated 96h of Hela cell, flow cytometer records apoptosis rate, result shows the Radix Paeoniae Alba 250 μ g/mL groups and the Radix Paeoniae Alba 250 μ g/mL compatibility Radix Angelicae Sinensis 125 μ g/mL combination group and the comparisons of blank group, and difference has statistical significance (P<0.01).But with the alone comparison of the 250 μ g/mL Radix Paeoniae Alba, the Radix Paeoniae Alba 250 μ g/mL compatibility Radix Angelicae Sinensis 125 μ g/mL combination group are failed the apoptosis (P<0.05) (referring to table 12) of co-induction Hela cell.Table 12 different experiments group Hela natural death of cerebral cells rate changes
| Group | Apoptosis rate |
| Blank group | 6.13±0.68 |
| Radix Angelicae Sinensis 125 μ g/mL | 6.77±0.69 |
| The Radix Paeoniae Alba 250 μ g/mL | *15.77±1.36 |
| The Radix Paeoniae Alba 250 μ g/mL+ Radix Angelicae Sinensis 125 μ g/mL | **10.17±1.04 |
* represent and relatively * * P<0.01 of blank experimental group
(3) Elisa detects the Radix Paeoniae Alba and the impact of Radix Angelicae Sinensis compatibility on Hela cell CyclinD1 expression
Experimental result shows: Hela cell is after different experiments group is processed 96h, only in the Radix Paeoniae Alba 250 μ g/mL compatibility Radix Angelicae Sinensis 125 μ g/mL combination group Hela cells, CyclinD1 expression and blank group relatively reduce, and difference has statistical significance (P<0.05).And CyclinD1 expression and the comparison of blank group in 250 alone group of the μ g/mL Radix Paeoniae Albas, alone group of Hela cell of Radix Angelicae Sinensis 125 μ g/mL, difference not statistically significant (P>0.05) (referring to table 13).
Table 13Hela cell CyclinD1 expression after different experiments group is processed 96h
| Group | CyclinD1(pg/mL) |
| Blank group | 101.00±47.27 |
| Radix Angelicae Sinensis 125 μ g/mL | 80.19±12.74 |
| The Radix Paeoniae Alba 250 μ g/mL | 101.94±58.77 |
| The Radix Paeoniae Alba 250 μ g/mL+ Radix Angelicae Sinensis 125 μ g/mL | *23.61±13.93 |
With relatively * P<0.05 of blank group
The research that experimental example 2 Elsholtzias are right
1 material
Human cervical carcinoma Hela cell is so kind as to give by central laboratory of Tianjin Cancer Institute; RPMI-1640 culture medium, GIBCO company of U.S. product;
Radix Et Rhizoma Rhei, Semen Persicae, the each single medicine of Hirudo and Radix Et Rhizoma Rhei are all adopted preparation with the following method with Semen Persicae, Hirudo by the compositions of different proportion compatibility respectively: get crude drug, soak 30min, add 8 times of water gagings to decoct three times, each 1.5 hours, filter merging filtrate, centrifugal, dry, pulverize into powder.Xeraphium need to be made into reagent the filtration sterilization of respective concentration with DMEM high glucose medium by experiment.
2 experimental techniques
Hela cell is cultivated in 5%CO2 incubator, and culture medium is the RPMI-l640 containing l0% deactivation calf serum, containing 1% dual anti-(penicillin and streptomycin).Within every 2～3 days, go down to posterity once, the trophophase cell of taking the logarithm is for experiment.5000/m1 Hela cell of the every hole inoculation of 24 orifice plate, inoculating dosing in latter 24 hours cultivates, choose Hela cell proliferation is had to obvious inhibiting Radix Et Rhizoma Rhei, itself and other drug are used and act on Hela cell by different proportion variable concentrations compatibility, be equipped with alone group of Radix Et Rhizoma Rhei, Semen Persicae, Hirudo, Radix Et Rhizoma Rhei and Semen Persicae in 1:1,2:1,1:2 ratio compatibility combination group, Radix Et Rhizoma Rhei and Hirudo in 1:1,2:1,1:2 ratio compatibility combination group, and negative control group.Add drug level with dosage group In vitro culture in following formula conversion Radix Et Rhizoma Rhei and different pharmaceutical compatibility: C (μ g/mL)=5D (mg/Kg/d); C is experiment in vitro desired concn, and D is clinical application concentration.Taking this concentration as intermediate concentration, respectively upwards, downward 2 times increase progressively and successively decrease, 6 Concentraton gradient are set continuously.In incubator, cultivate 96h, light is respectively organized cellular morphology through Microscopic observation and is changed, rear collecting cell, row trypan blue counting.
In utilization, imitate principle judgement associating drug effect: middle effect concentration (Dm), be the calculating of half-inhibition concentration (IC50), calculate medicine group cell fu(survival rate fraction of unaffeeted cells according to trypan blue exclusion viable count) and fa(suppression ratio fraetion of affected cells)
The average viable count of the average viable count/matched group of fu=test group
fa=1-fu
Being taken the logarithm in middle efficacious prescriptions journey fa/fu=(D/Dm) m both sides, (D is drug level; Dm is middle effect concentration) equation:
log(fa/fu)=mLogD-mLogDm
Thereby Dx=Dm × [fa/ (l-fa)] l/m
If Y=log (fa/fu), X=logD, obtains linear equation:
The slope of Y=mX+a(m equation, a is equation intercept)
When Fa=0.5, X=logDm=-a/m, the Dm value while calculating the alone and use in conjunction of medicine
Applying this formula Dx=Dm × [fa/ (1-fa)] 1//m calculates and reaches various effects (fa=0.1,0.2,0.3 ... 0.9) the alone and needed drug level of use in conjunction (D) of two kinds of medicines time
CI (The Combination index) value when calculating two medicines and share according to the amount-effect formula in week-Te Shi association index method
Clx=D1/Dxl+D2/Dx2
Attention: Dl in formula, D2 when share, the shared concentration of two medicines when effect reaches X, Dxl, Dx2 was two prescription used times, concentration separately when effect reaches X.In factor alpha basis, effect mapping is determined, when two medicines mappings are parallel to each other, α value is 0, otherwise is 1.
Result is judged: CI<l represents that when two medicines share, producing collaborative (synergism) acts on; CI=1 represents that when two medicines share, producing addition (additivity) acts on; CI>l represents that two medicines produce antagonism (antagonism) effect while share.
Middle effect concentration and associating drug effect are by CalcuSyn computed in software matching chart.
3 statistical method
Application SPSS16.0 statistics analysis software package, experimental data is with mean ± standard deviation
represent, under the condition of testing data normal distribution and homogeneity of variance, between many groups, data relatively adopt variance analysis, respectively organize relatively checking with LSD-t of group difference.With P < 0.05 for there being statistical significance.
4 experimental results
4.1 Radix Et Rhizoma Rhei and the impact of Semen Persicae compatibility on Hela cell proliferation
Radix Et Rhizoma Rhei and Semen Persicae are alone and share (Radix Et Rhizoma Rhei: Semen Persicae=1:1,1:2 and 2:1) viable count after human cervical carcinoma Hela cell's strain 96h, calculate the cell inhibitory rate under the each concentration of each experimental group.Application Excel and CalcuSyn computed in software Radix Et Rhizoma Rhei and Semen Persicae share in the time of different effect association index value (CI) statistical analysis of Hela cell are shown, Radix Et Rhizoma Rhei and Semen Persicae have suppressed antagonism (CI>1) (refer to show 14-table 16) to the propagation of Hela cell by different proportion compatibility when the 0.1<Fa<0.9.
Table 14 variable concentrations Radix Et Rhizoma Rhei and Semen Persicae are alone to the cytostatic effect Fa of Hela
Table 15 Radix Et Rhizoma Rhei and Semen Persicae share the cytostatic effect Fa to Hela
Table 16 Radix Et Rhizoma Rhei and the CI index of Semen Persicae different proportion compatibility to Hela Growth of Cells
4.2 Radix Et Rhizoma Rhei and the impact of Hirudo compatibility on Hela cell proliferation
The each combination group CI of application CalcuSyn computed in software shows: Radix Et Rhizoma Rhei and Hirudo are pressed 1:1, and 2:1 plays antagonism inhibitory action (CI>1) (referring to table 17-table 19) to Hela cell when 1:2 ratio compatibility.
Table 17 variable concentrations Radix Et Rhizoma Rhei and Hirudo are alone to the cytostatic effect Fa of Hela
Table 18 Radix Et Rhizoma Rhei and Hirudo are share the cytostatic effect Fa to Hela
Table 19 Radix Et Rhizoma Rhei and the CI index of Hirudo different proportion compatibility to Hela Growth of Cells
Detailed description of the invention
Embodiment 1 oral liquid
Prescription crude drug composition: Radix Paeoniae Alba 30g, Radix Angelicae Sinensis 30g;
Get the crude drug of recipe quantity, decoct with water 2 times, 2 hours for the first time, 1.5 hours for the second time, collecting decoction, filters, and filtrate is concentrated, concentrated solution adds ethanol to containing alcohol amount to 70%, leave standstill, filter, filtrate recycling ethanol is extremely without alcohol taste, and to be concentrated into relative density be 1.15(60 DEG C), add conventional adjuvant to make oral liquid.
Embodiment 2 tablets
Prescription crude drug composition: Radix Paeoniae Alba 30g, Radix Angelicae Sinensis 15g;
Get the crude drug of recipe quantity, add 5 times of amount 70% alcohol reflux 2 times, each 1.5 hours; Merge extractive liquid,, filters, and reclaims ethanol concentrated; Concentrated solution drying under reduced pressure, is ground into fine powder, adds conventional adjuvant, mixes; Dry-pressing is granulated, and tabletting, to obtain final product.
Embodiment 3 capsules
Prescription crude drug composition: Radix Paeoniae Alba 30g, Radix Angelicae Sinensis 60g;
Get the crude drug of recipe quantity, add 10 times of amount methanol supersound extraction 3 times, 40min for the first time, the 2nd, 3 each 20min, merge extractive liquid,, filters concentrating under reduced pressure; Concentrated solution drying under reduced pressure, is ground into fine powder, adds conventional adjuvant, mixes; Dry-pressing is granulated, and incapsulates, and to obtain final product.
Embodiment 4 granules
Prescription crude drug composition: Radix Paeoniae Alba 30g, Radix Angelicae Sinensis 120g;
Get the crude drug of recipe quantity, soak 30min, add 8 times of water gagings to decoct three times, each 1.5 hours, filter, merging filtrate, concentrated; Concentrated solution, by macroporous resin, is first used 5 times of water gaging eluting, and eluent is abandoned or adopted, then with adding 70% ethanol elution, collects eluent, and decompression recycling ethanol is extremely without alcohol taste; 80 DEG C of following drying under reduced pressure, are ground into fine powder, add adjuvant, mix; Dry-pressing is granulated, and to obtain final product.
Embodiment 5 oral liquids
Prescription crude drug composition: Radix Paeoniae Alba 30g, Radix Angelicae Sinensis 90g;
Get recipe quantity crude drug, decoct with water 2 times, each 1.5 hours, collecting decoction, filtered, filtrate is concentrated, and concentrated solution adds ethanol to containing alcohol amount to 80%, leaves standstill, and filters, filtrate recycling ethanol is to without alcohol taste, and to be concentrated into relative density be 1.15(60 DEG C), add adjuvant, make oral liquid.
Embodiment 6 drop pill
Prescription crude drug composition: Radix Paeoniae Alba 30g, Radix Angelicae Sinensis 9g;
Get the crude drug of recipe quantity, add 8 times of water gaging dipping 6h, percolation 24h, flow velocity 2L/h.Collect percolate, centrifugal, upper macroporous adsorptive resins, first washes with water, then uses 60% ethanol elution, collects ethanol elution, and filtrate is concentrated, then adds acceptable adjuvant in pharmacy to make drop pill according to the routine techniques of this area preparation.
Embodiment 7 tablets
Prescription crude drug composition: Radix Paeoniae Alba 30g, Radix Angelicae Sinensis 6g;
Get the crude drug of recipe quantity, add 5 times of amount 60% alcohol reflux 2 times, each 1.5 hours; Merge extractive liquid,, filters, and reclaims ethanol concentrated; Concentrated solution drying under reduced pressure, is ground into fine powder, adds conventional adjuvant, mixes; Dry-pressing is granulated, and tabletting, to obtain final product.
Embodiment 8
Prescription crude drug composition: Radix Paeoniae Alba extract 30g, Radix Angelicae Sinensis extract 30g;
Described Radix Paeoniae Alba extract, Radix Angelicae Sinensis extract are respectively the extract that the Radix Paeoniae Alba, Radix Angelicae Sinensis prepare through 60% alcohol reflux.By said extracted thing drying under reduced pressure, pulverize as fine powder, mix, add the agent of conventional adjuvant granulation.
Embodiment 9
Prescription raw material composition: Radix Paeoniae Alba extract 30g, Radix Angelicae Sinensis extract 15g;
Described Radix Paeoniae Alba extract, Radix Angelicae Sinensis extract are respectively the Radix Paeoniae Alba, Radix Angelicae Sinensis and boil the extract preparing through decocting.By said extracted thing drying under reduced pressure, pulverize as fine powder, mix, add conventional adjuvant to make tablet.
Embodiment 10
Prescription raw material composition: Radix Paeoniae Alba extract 30g, Radix Angelicae Sinensis extract 60g;
Described Radix Paeoniae Alba extract, Radix Angelicae Sinensis extract are respectively the extract that the Radix Paeoniae Alba, Radix Angelicae Sinensis prepare through acetone reflux, extract.By said extracted thing drying under reduced pressure, pulverize as fine powder, mix, add conventional adjuvant to make capsule.
Embodiment 11
Prescription raw material composition: Radix Paeoniae Alba extract 30g, Radix Angelicae Sinensis extract 90g;
Described Radix Paeoniae Alba extract, Radix Angelicae Sinensis extract are respectively the extract that the Radix Paeoniae Alba, Radix Angelicae Sinensis prepare through aqueous extraction-alcohol precipitation technology, and its alcohol precipitation concentration is that 70% alcoholic solution percolation extracts the extract obtaining; By said extracted thing drying under reduced pressure, be ground into fine powder, add conventional adjuvant, mix; Dry-pressing is granulated, and tabletting, to obtain final product.
Claims (10)
1. a Chinese medicine composition with antitumaous effect, is characterized in that, the crude drug of this Chinese medicine composition is mainly made up of the Radix Paeoniae Alba, Radix Angelicae Sinensis.
2. Chinese medicine composition as claimed in claim 1, is characterized in that, this Chinese medicine composition is made up of the crude drug of following weight ratio:
The Radix Paeoniae Alba: Radix Angelicae Sinensis=1:(0.2-4);
Or, the Radix Paeoniae Alba: Radix Angelicae Sinensis=1:(0.3-3.5);
Or, the Radix Paeoniae Alba: Radix Angelicae Sinensis=1:(0.4-3);
Or, the Radix Paeoniae Alba: Radix Angelicae Sinensis=1:(0.5-2.5);
Or, the Radix Paeoniae Alba: Radix Angelicae Sinensis=1:(0.5-2.2).
3. Chinese medicine composition as claimed in claim 2, is characterized in that, this Chinese medicine composition is made up of the crude drug of following weight ratio:
The Radix Paeoniae Alba: Radix Angelicae Sinensis=1:0.5;
Or, the Radix Paeoniae Alba: Radix Angelicae Sinensis=1:1;
Or, the Radix Paeoniae Alba: Radix Angelicae Sinensis=1:2.
4. as described in as arbitrary in claim 1-3, the preparation method of Chinese medicine composition, is characterized in that, the method comprises:
Get in proportion crude drug, the organic solvent extraction dissolving each other with water or with water;
Or, get in proportion crude drug, adopt decoction and alcohol sedimentation technique preparation; Wherein said alcohol precipitation concentration is 50-90%.
5. the preparation method of Chinese medicine composition as claimed in claim 4, is characterized in that, the described organic solvent dissolving each other with water is selected from one or more in methanol, ethanol, acetone; Described extracting method comprises any one mode decocting in extraction, reflux, extract,, immersion extraction, supersound extraction or percolation extraction, or the combination of Different Extraction Method.
6. a Chinese medicine composition with antitumaous effect, is characterized in that, this Chinese medicine composition is made up of the raw material of following weight ratio:
Radix Paeoniae Alba extract: Radix Angelicae Sinensis extract=1:(0.2-4).
7. Chinese medicine composition as claimed in claim 6, is characterized in that, this Chinese medicine composition is made up of the raw material of following weight ratio:
Radix Paeoniae Alba extract: Radix Angelicae Sinensis extract=1:(0.3-3.5);
Or, Radix Paeoniae Alba extract: Radix Angelicae Sinensis extract=1:(0.4-3);
Or, Radix Paeoniae Alba extract: Radix Angelicae Sinensis extract=1:(0.5-2.5);
Or, Radix Paeoniae Alba extract: Radix Angelicae Sinensis extract=1:(0.5-2.2).
8. Chinese medicine composition as claimed in claim 7, is characterized in that, this Chinese medicine composition is made up of the raw material of following weight ratio:
Radix Paeoniae Alba extract: Radix Angelicae Sinensis extract=1:0.5;
Or, Radix Paeoniae Alba extract: Radix Angelicae Sinensis extract=1:1;
Or, Radix Paeoniae Alba extract: Radix Angelicae Sinensis extract=1:2.
9. the application of the Chinese medicine composition as described in as arbitrary in claim 1-3,6-8 in preparation treatment cancer drug.
10. the application of the Chinese medicine composition as described in as arbitrary in claim 1-3,6-8 in preparation treatment cervical cancer medicine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310100488.0A CN104069194B (en) | 2013-03-26 | 2013-03-26 | A kind of Chinese medicine composition with antitumaous effect and its production and use |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310100488.0A CN104069194B (en) | 2013-03-26 | 2013-03-26 | A kind of Chinese medicine composition with antitumaous effect and its production and use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104069194A true CN104069194A (en) | 2014-10-01 |
| CN104069194B CN104069194B (en) | 2017-03-29 |
Family
ID=51591060
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310100488.0A Active CN104069194B (en) | 2013-03-26 | 2013-03-26 | A kind of Chinese medicine composition with antitumaous effect and its production and use |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104069194B (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104352608A (en) * | 2014-10-14 | 2015-02-18 | 武汉科德中医医院有限公司 | Traditional Chinese medicine capable of benefiting qi, activating blood circulation, softening hardness, dissipating stagnation, realizing detoxification and relieving pain as well as preparation method thereof |
| CN104544106A (en) * | 2015-02-24 | 2015-04-29 | 刘永 | Preparation method of panacis quinquefolii radix chewable tablet |
| CN105749099A (en) * | 2016-03-30 | 2016-07-13 | 三株福尔制药有限公司 | Probiotic fermented traditional Chinese medicine composition for treating gastric cancer and preparation method and application thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004307458A (en) * | 2003-04-07 | 2004-11-04 | Korea Atom Energ Res Inst | Galenical composition having anticancer/immune/hematopoietic function enhancing effect and oxidative living body damage suppressing effect and manufacturing method thereof |
| CN101204552A (en) * | 2007-11-29 | 2008-06-25 | 北京中科雍和医药技术有限公司 | Chinese traditional medicine composite for breast cancer and cervical carcinoma and preparation method thereof |
| CN102475822A (en) * | 2010-11-27 | 2012-05-30 | 冯文明 | Oral liquid capable of preventing and treating cervical cancer |
| CN102716417A (en) * | 2012-06-15 | 2012-10-10 | 祁连明 | Traditional Chinese medicine preparation for treating gynaecopathia and preparation method of preparation |
-
2013
- 2013-03-26 CN CN201310100488.0A patent/CN104069194B/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004307458A (en) * | 2003-04-07 | 2004-11-04 | Korea Atom Energ Res Inst | Galenical composition having anticancer/immune/hematopoietic function enhancing effect and oxidative living body damage suppressing effect and manufacturing method thereof |
| CN101204552A (en) * | 2007-11-29 | 2008-06-25 | 北京中科雍和医药技术有限公司 | Chinese traditional medicine composite for breast cancer and cervical carcinoma and preparation method thereof |
| CN102475822A (en) * | 2010-11-27 | 2012-05-30 | 冯文明 | Oral liquid capable of preventing and treating cervical cancer |
| CN102716417A (en) * | 2012-06-15 | 2012-10-10 | 祁连明 | Traditional Chinese medicine preparation for treating gynaecopathia and preparation method of preparation |
Non-Patent Citations (5)
| Title |
|---|
| MASATOSHI HARADA ET AL.: "EFFECT OF JAPANESE ANGELICA ROOT AND PEON" ROOT ON UTERINE CONTRACTION IN THE RABBIT IN SITU", 《J.PHARM DYN》, no. 7, 31 December 1984 (1984-12-31), pages 304 - 311 * |
| SATOSHI USUKI，M.D.: "Blended Effects of Herbal Components of Tokishakuyakusan on Somatomedin C/Insulin一like Growth Factor 1 Level in Rat Corpus Luteum", 《AMERICAN JOURNAL OF CHINESE MEDICINE》, no. 1, 31 December 1991 (1991-12-31), pages 61 - 64 * |
| W.CAO ET AL.: "A novelpolysaccharide,isolatedfrom Angelica sinensis (Oliv.) Diels induces the apoptosis of cervical cancer HeLa cells throughan intrinsic apoptotic pathway", 《PHYTOMEDICINE》, no. 17, 31 December 2010 (2010-12-31), pages 598 - 605 * |
| 杨士友等: "白芍中白芍苷提取和纯化工艺的研究", 《安徽医药》, vol. 8, no. 1, 29 February 2004 (2004-02-29), pages 21 - 23 * |
| 王文君等: "白芍苷R1体外抗细胞增殖活性初步研究", 《广州中医药大学学报》, vol. 22, no. 1, 31 January 2005 (2005-01-31), pages 53 - 55 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104352608A (en) * | 2014-10-14 | 2015-02-18 | 武汉科德中医医院有限公司 | Traditional Chinese medicine capable of benefiting qi, activating blood circulation, softening hardness, dissipating stagnation, realizing detoxification and relieving pain as well as preparation method thereof |
| CN104544106A (en) * | 2015-02-24 | 2015-04-29 | 刘永 | Preparation method of panacis quinquefolii radix chewable tablet |
| CN105749099A (en) * | 2016-03-30 | 2016-07-13 | 三株福尔制药有限公司 | Probiotic fermented traditional Chinese medicine composition for treating gastric cancer and preparation method and application thereof |
| CN105749099B (en) * | 2016-03-30 | 2019-09-13 | 三株福尔制药有限公司 | A kind of probiotics fermention Chinese medicine composition and its preparation method and application for treating gastric cancer |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104069194B (en) | 2017-03-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103768534A (en) | Traditional Chinese medicinal composition with anti-tumor activity | |
| CN101647842A (en) | Fructus Podophylli extract and application thereof | |
| CN104706855A (en) | Preparation methods and application of Jichuan decoction traditional Chinese medicine extract | |
| CN101904974B (en) | Chinese medicinal composition for treating malignant tumor diseases and preparation method thereof | |
| CN101502579A (en) | Chinese medicinal composition for treating digestive tumor and preparation method thereof | |
| CN104069194A (en) | A traditional Chinese medicine composition having anticancer effects and a preparing method and uses thereof | |
| CN101850032A (en) | Anti-tumor traditional Chinese medicine composition and preparation method and application thereof | |
| CN1775267A (en) | Kaikoujian extract, Its preparing method and use | |
| CN108434399A (en) | A kind of Chinese medicine composition and preparation method of anti-curing oncoma | |
| CN101172143A (en) | Chinese traditional medicine compound, method for preparing the same and use thereof | |
| CN101120977B (en) | Medicine for treating tumor | |
| CN102626465B (en) | Longchai decoction pellet and preparation method thereof | |
| CN103550718A (en) | Traditional Chinese medicine composition for treating lung cancer | |
| CN103191267B (en) | Traditional Chinese medicine composition for treating liver cancers | |
| CN104069192B (en) | A traditional Chinese medicine composition having anticancer effects and a preparing method and uses thereof | |
| CN102091312A (en) | Ginger and wild pepper composition and preparation method thereof, and application of ginger and wild pepper composition in preparation of attenuation and synergy medicaments for radiotherapy and chemotherapy of cancers | |
| CN101549032B (en) | Drug composition with the effect of anti-lung cancer and application in preparing anti-lung cancer drug | |
| CN104069273A (en) | A traditional Chinese medicine composition having anticancer effects and a preparing method and uses thereof | |
| CN100427099C (en) | Juglans mandshurica maxim pdysaccharide preparation capable of effectively treating brain cancer and its preapring method | |
| CN104257955A (en) | Anti-hepatoma traditional Chinese medicine mixture containing arisaema amurense and production method of anti-hepatoma traditional Chinese medicine mixture | |
| CN103655600A (en) | Drug composition for treating cancers, preparation method and applications | |
| CN102139037A (en) | Application of rhizoma paridis total saponins in preparation of adjuvant drugs of anti-cancer drugs | |
| CN102416087A (en) | Chinese medicinal composition for treating pelvic inflammatory disease and preparation method as well as application thereof | |
| CN103191268B (en) | Traditional Chinese medicinal composition for treating lung cancer | |
| CN102552848B (en) | Ginger and kudzuvine root composition for reducing vomiting caused by cancer chemotherapy and improving chemotherapy effects, and preparation method for ginger and kudzuvine root composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |